



TRIDENT LIFELINE LIMITED
(Formerly Trident Lifeline Private Limited)

CIN No. : L51909GJ2014PLC078227

GST No. : 24AAECT8906D1ZG

Date: December 24, 2024

BSE Limited 14th Floor, P. J. Towers, Dalal Street, Fort, Mumbai - 400001.	Stock ID: TLL Scrip Code: 543616
--	---

Sub: Revised Intimation under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations') - Acquiring 51% stake and making a Subsidiary

Ref: Our intimation letter dated December 23, 2024.

Dear Sir/Ma'am,

Please refer to our earlier intimation letter dated December 23, 2024 regarding proposed acquisition of 51 % of equity share of **TRIDENT MEDIQUIP LIMITED ("TMQL")** (CIN: U33309GJ2019PLC110421) from existing shareholders of the Company and making TMQL as a subsidiary of the Company Pursuant to Regulation 30 of the SEBI Listing Regulations.

You are requested to take on record following inadvertent errors/ corrections / changes required to above referred letter:

Cost of acquisition or the price at which the shares are acquired as mentioned in point 8 in information under Regulation 30 of SEBI(LODR) Regulations, 2015 and SEBI Master Circular will be Rs. 11.32/- per share instead of Rs. 10/- per share.

Accordingly, please find below the revised intimation after making the necessary changes as mentioned above for your records:

Thanking you,
For Trident Lifeline Limited

NIKITA SHARMA
COMPANY SECRETARY AND COMPLIANCE OFFICER
M. NO.: A60595

TRIDENT LIFELINE LIMITED

(Formerly Trident Lifeline Private Limited)

Revised Information under Regulation 30 of SEBI (LODR) Regulations, 2015 and SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024.

Sr. No.	Particulars	Details
1	Name of the target entity, details in brief such as size, turnover etc.	<p>TRIDENT MEDIQUIP LIMITED (CIN: U33309GJ2019PLC110421) Company incorporated under the provisions of the Companies Act, 2013, having its Registered Office in Surat, Gujarat.</p> <p>Capital Details: Authorized Share Capital: Rs. 8,00,00,000 /- divided into 80,00,000 Equity Shares of Rs.10/- each</p> <p>Paid-up Share Capital: Rs. 7,78,00,000/- divided into 77,80,000 Equity Shares of Rs.10/- each</p> <p>Turnover: Rs. 20,58,08,887/-</p>
2	whether the acquisition would fall within related party transaction(s) and whether the promoter/promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"	<p>Yes, TRIDENT MEDIQUIP Limited (TMQL), a public Limited Company in which Mr. Hardik Jigishkumar Desai, Amit Bhupendra Halvawala and Mr. Chetan Chandrakant Jariwala (director's Relative) are member cum Director and all of above are part of promoters/promoter group/board of acquiring Company i.e being Trident Lifeline Limited (The Company), have an interest in the entity being acquired (TMQL).</p> <p>The transaction is being undertaken on an arm's length basis.</p>
3	Industry to which the entity being acquired belongs	Pharmaceuticals Industry
4	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its	This acquisition would allow the company to partner with the leading and fast-growing market of medical & surgical and/or diagnostic equipments,

TRIDENT LIFELINE LIMITED

(Formerly Trident Lifeline Private Limited)

	business is outside the main line of business of the listed entity)	along with pharmaceuticals and allied products.
5	Brief details of any governmental or regulatory approvals required for the acquisition.	The acquisition is within the overall limit approved by the Shareholders of the Company under Section 186 of the Companies Act, 2013.
6	Indicative time period for completion of the acquisition	Approx. One Month
7	Consideration - whether cash consideration or share swap and details of the same;	Acquisition of shares is by way of Cash
8	Cost of acquisition or the price at which the shares are acquired;	Rs 11.32/- per share
9	Percentage of shareholding / control acquired and / or number of shares acquired;	Pre-acquisition holding: NIL Post-acquisition holding (Proposed): 39,67,800 equity shares of Rs 10/- amounting of Rs. 3,96,78,000/- constituting 51% equity stake
10	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	Date of incorporation: October 19, 2019 Product/line of business: Pharmaceuticals Industry Last 3 years' turnover: Financial year 2021-22: 35,08,25,152.94/- Financial year 2022-23: 28,77,39,633.10/- Financial year 2023-24- Rs. 20,58,08,887/- Presence of entity: India